entertainment -WSS

entertainment

author：entertainment 2025-09-30 18:34:52 - browse：38

Maze Therapeutics CEO Jason Coloma Courtesy

After seeing its last deal go bust in the face of regulatory scrutiny, Maze Therapeutics has found another suitor for its experimental Pompe disease treatment.

Bay Area-based Maze and Shionogi said Friday that the Japanese pharma company had licensed the drug, called MZE001, with an upfront payment of $150 million. The global deal includes additional, undisclosed payments if the oral medication, which is in clinical testing, meets certain regulatory and commercial goals.

Last year, Sanofi, the French pharma giant, was set to pay $150 million in cash and stock to Maze before the transaction fell apart.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： Chemotherapy drug shortage eases slightly but still widespread

hotspot

WSS

Liquid biopsy for lung cancer is launched by Delfi

3 questions for the future of Biden's cancer moonshot

In science, is the line between industry and academia shifting?

What to expect at HLTH 2023, the health care industry conference

AstraZeneca bets AAV gene therapy will still deliver the goods

Complete sequence of Y chromosome published for first time

Wikipedia

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Jerome Adams on the need for new antivirals for Covid

Diversity in medical illustrations gets boost from Chidiebere Ibe

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

VC firm General Catalyst wants to buy a health system

ChatGPT in medicine: STAT answers readers' burning questions

Sana to lay off nearly a third of staff, de

Novavax promises a turnaround & Lilly roils the obesity market

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

Moonlake's readout produced a cash windfall. Risks remain

Complete sequence of Y chromosome published for first time

hotspot

When women are denied an abortion, their children fare worse than peers

Diversity in medical illustrations gets boost from Chidiebere Ibe

FDA rejects Alnylam's heart disease treatment over insufficient data

Colorectal cancer study finds potential in overlooked immune cell

Bristol 'take

Study finds new variant for Parkinson’s in African populations

knowledge

hotspot

entertainment

entertainment